Rockbridge Investment Management, Lcc Biomarin Pharmaceutical Inc Transaction History

Rockbridge Investment Management, Lcc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $84,985 - $109,838	-1,115 Closed	0 $0
Q3 2022 May 28, 2024	SELL	$82.16 - $96.94 $4,929 - $5,816	-60 Closed	0 $0
Q1 2022 May 28, 2024	BUY	$74.28 - $92.69 $4,456 - $5,561	60 New	60 $4,000
Q1 2021 May 20, 2021	BUY	$74.73 - $90.69 $4,483 - $5,441	60 Added 5.69%	1,115 $84,000
Q3 2020 Nov 03, 2020	BUY	$71.87 - $131.03 $75,822 - $138,236	1,055 New	1,055 $80,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Rockbridge Investment Management, Lcc, based on Form 13F filings with the SEC.

Stay updated on Rockbridge Investment Management, Lcc with notifications on news.